SPA set for rivipansel Phase 3 study

|By:, SA News Editor

GlycoMimetics (GLYC +10%) reports that development partner Pfizer (PFE +0.5%) and the FDA have agreed on the special protocol assessment (SPA) for the planned Phase 3 clinical trial for rivipansel as a treatment for patients with sickle cell disease who are hospitalized for vaso-occlusive crisis. Pfizer intends to start the trial before the end of 2014.

Rivipansel is both Orphan Drug and Fast Track-designated.